Welcome to the Tumour Foundation of BC!

Incredible news to take with you into the long weekend. 

Approval of Koselugo (selumetinib) increases potential for successful tumor reduction in patients. This is a major milestone which could benefit over 2.5 million living with NF!! Learn more at https://www.ctf.org/news/fda-approves-first-ever-treatment-for-nf.

NF and COVID-19

What is Neurofibromatosis (NF)?

Neurofibromatosis (NF) encompasses a set of distinct genetic disorders (NF1, NF2 and Schwannomatosis) that cause tumours to grow along nerves and can affect the development of non-nervous tissues such as bones and skin. NF causes tumours to grow anywhere on or in the body and can also cause additional complications such as disfigurement, bone deformities and learning disabilities.

NF is more common than cystic fibrosis, Duchenne's muscular dystrophy and Huntington’s disease combined.

Faces of NF Brochure